Hemophagocytic lymphohistiocytosis (HLH), a life-threatening hyper-inflammation syndrome, is classified into primary and secondary forms. 1 Primary HLH is caused by gene mutations (PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST and AP3B1) resulting in impaired cytotoxicity of natural killer (NK) cells and cytotoxic T lymphocytes. HLH also presents in immunodeficiencies driven by uncontrolled EBV infection, which include X-linked lymphoproliferative syndrome (XLP) 1, XLP2, ITK deficiency and CD27 deficiency, caused by defects in SH2D1A, BIRC4, ITK and CD27, respectively. Secondary HLH often occurs in adults and is associated with various conditions. Primary HLH can occur at any age, although it predominately affects pediatric patients. In contrast to the well-documented efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric HLH, the role of HSCT in adult HLH is unclear. 2 In particular, few reports address the treatment of adult primary HLH with haploidentical HSCT.
We retrospectively evaluated three adult patients with primary HLH who underwent haploidentical HSCT at our institution. The patients were consecutively recruited between June 2012 and March 2016. All patients met the HLH-2004 diagnostic criteria 3 and were treated with the HLH-94 regimen 4 (Table 1) . Patient 3 underwent DEP salvage therapy 5 because of no response to the initial treatment with HLH-94. All patients underwent haploidentical HSCT from a 5/10 HLA allele-matched related donor because no matched donor was identified. All family members were screened for the HLH-associated genes to exclude the possibility of carrying this disease. Donors without mutations were selected for patient 1 and patient 3. Although a heterozygous carrier, the son of patient 2 was chosen as his donor as normal NKcell degranulation was confirmed in a CD107a test (Figure 1 ). All patients were conditioned with TBI 800 cGy (400 cGy fractions once daily on days − 8 and − 7); 10 mg/kg/dose of VP-16 once daily on days − 6 and − 5; and 1.8 g/m 2 /dose of cyclophosphamide (CY) once daily (days − 4 and − 3). The total dose of rabbit anti-human thymocyte globulin (ATG; Sanofi, China) was 8 mg/kg; the fraction was administered once daily on days − 3, − 2 and − 1. Beginning on day − 3, donors were administered subcutaneous granulocyte CSF at a dose of 7.5 μg/kg/day for 5 days. Peripheral blood cells were harvested from the donor on days 01 and 02 and immediately infused into the patients. GvHD prophylaxis 6 comprised an IV dose (2.5 mg/kg/day) of cyclosporine A (CsA) beginning on day − 8; an oral dose (500 mg twice daily) of mycophenolate mofetil was administered on days − 8 to +28 and then adjusted to a one-half dose after engraftment; and methotrexate was administrated at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11. Alprostadil was administered to prevent hepatic vein embolization at a dose of 10 μg/day on days − 8 to +30. 7 Prophylaxis for hemorrhagic cystitis included fluid transfusion, urinary alkalization, administration of alprostadil and mesna. The treatment strategy comprised a bladder flush and local drug application. Antibiotics were ceased after engraftment. To prevent CMV infection, ganciclovir was used before HSCT and discontinued on day -1; acyclovir was administered starting on day +1. EBV and CMV were routinely screened using quantitative real-time PCR every 3-4 days. Elevated blood viral-DNA load was treated by reducing immunosuppressors until a negative viral-DNA load was obtained.
All three patients presented with a high fever as their initial clinical feature. Anti-infection treatments had no effect. HLH was suspected based on laboratory findings including liver and coagulation function abnormalities, elevated serum ferritin and decreased NK-cell activity. Diagnosis of primary HLH was confirmed by mutations detected in HLH-associated genes (Table 1) . Representative results from a genetic test for patient 2 and his family are presented in Figure 1 . Patients 1 and 2 were found to have an EBV infection on admission. Their blood EBV-DNA load became negative during induction therapy. All patients achieved remission at HSCT. Their clinical features were significantly improved after HSCT (data not shown). All patients demonstrated complete chimerism on day +20. No patient developed graft rejection or underwent a second transplant if donor chimerism remained complete after day +20. The acute GvHD that occurred in patients 2 and 3 resolved after maintaining a CsA blood concentration of 150-250 ng/mL and with methylprednisolone (1-2 mg/kg). As for patient 2, lichenification was found in the mouth 2 months after transplant. This finding was considered a local chronic GvHD with no treatment, and the patient remained well. EBV viremia occurred in patients 2 and 3, and both patients' results became negative after reducing the immunosuppressors. There was no evidence of EBV disease. At the end of follow-up, all patients remained well with stable engraftment. Post-transplant genetic testing confirmed the mutations in patients were replaced by the donor genotypes.
For primary HLH, the age of onset and clinical presentation might be affected by the type and combination of mutations in HLH-associated genes, 8 if mutations were homozygous, heterozygous, compound heterozgous, hemizygous and so on. Patient 1 had XLP1 rather than FHL2 for carrying a PRF1 p.L43M mutation from his father and an SH2D1A p.A3S mutation from his mother. It is unknown if there is any interaction between these two proteins. Patient 3 had a homozygous missense mutation in PRF1 p.T450M. This mutation was determined to be deleterious and it has been reported in the literature, that this mutation is known to be associated with late onset. 9 Moreover, infection triggers such as EBV may have a role in HLH onset and affect clinical severity. Patient 2 and his sister had the same homozygous missense mutation in UNC13D p.G863D and abnormal NK-cell degranulation in a CD107a assay, but his sister was asymptomatic without obvious triggers and hence did not undergo HSCT. It is in dispute whether his sister requires pre-emptive HSCT. There are risks for haploidentical HSCT with the existence of transplantrelated mortality (TRM). For the asymptomatic individual with inborn errors but no obvious predisposing factors, whether they can benefit from pre-emptive HSCT needs to be verified in more prospective studies. Active EBV infections were demonstrated in patients 1 and 2. The genetic variants they had may result in residual NK-cell activity, which could be the basis of their late-onset HLH triggered by factors such as EBV infection. Patient 2 underwent a CD107a degranulation assay to be screened for primary HLH when this assay was available at our institute that was consistent with the genotyping results. For adult patients with refractory or relapsing HLH, if there are no identified triggers but a sustained decrease in CD107a degranulation assay and NK-cell activity assay, it is suggested to perform the genetic analysis for the diagnosis.
Early studies on HSCT in children with HLH used myeloablative conditioning (MAC) (busulfan/CY/VP-16, plus or minus ATG), which was associated with a significantly high TRM rate with 430% of patients experiencing an early death from TRM within 100 days post SCT. 2 HSCT with a reduced-intensity conditioning (RIC) regimen (fludarabine, melphalan or treosulfan and alemtuzumab) achieved less TRM. Moreover, this protocol significantly improved the survival rate from 43% with MAC to an estimated 3-year median survival rate of 92% with RIC. 10, 11 On the basis of these data, RIC is currently used as the standard protocol for pediatric HLH that necessitates HSCT. 11 There are a few published reports that address treatment of adult HLH with haploidentical HSCT. 2 Moreover, because the three patients in our study underwent haploidentical HSCT, intensified immunosuppression was necessary to facilitate engraftment and overcome the barrier of unmatched HLA. To avoid increased mortality from graft failure, we used MAC instead of RIC in our study. As RIC is currently the standard protocol, our efforts were geared towards using RIC; presently, we are studying this approach to treat adults with H. Furthermore, alternative approaches for haploidentical HSCT in HLH could also be effective. In vitro T-cell depletion to prevent GvHD in the combination with MAC, which is used in most centers for HSCT in inborn errors might be a good choice. 12 As widely used nowadays for haploidentical HSCT also in non-malignant diseases, bone marrow transplantation using RIC conditioning followed by GvHD prevention with CY should also be considered. 13 Venoocclusive disease (VOD) and (noninfectious) pneumonitis are a major part of TRM in MAC.
14 This may be because patients with HLH often have liver and lung damage and are prone to develop VOD and pneumonitis, whereas conditioning with a busulfan-based protocol. 14 The three patients in our study underwent TBI instead of busulfan to avoid increased risk of VOD and pneumonitis. All three patients tolerated conditioning without significant regimen-associated toxicity, and the occurrence of GvHD I-III was acceptable. High-resolution HLA typing was performed by PCR amplification with sequence-specific primers (SSP) to determine HLA-A, -B, -Cw, -DRB1 and -DQB1 locus types.
Letter to the Editor Engraftment was successful with neutrophil and platelet achieving at the same time. EBV disease did not occur; possible reasons are as follows: the EBV infection had resolved during induction; EBV was routinely screened after HSCT; immunosuppressors were reduced or discontinued once a viral infection was identified.
In summary, we reported on our experiences regarding the successful treatment of three adults with primary HLH who underwent haploidentical HSCT. Additional study is warranted to optimize and confirm this approach. assay to measure NK-cell degranulation for P2 and his family. Assay followed the method as in the published paper. 15 ΔCD107a was calculated by % CD107a-positive cells after stimulation − % CD107a-positive cells without stimulation. On stimulation, significant reduced levels of surface CD107a in NK cells were found in P2 and his sister compared with the normal CD107a expression in healthy control, his father and son. These results indicated the homozygous mutation in UNC13D p.G863D found in P2 and his sister having functional consequences in the encoded protein, which resulted in impaired degranulation in NK cells. The graphs on the bottom of this panel show normal ΔCD107a which indicates the restored NK-cell degranulation for P2 after HSCT, which was consistent with the post-HSCT genotyping that the mutations in P2 replaced by the donor genotype.
